Record-Breaking Results and Moody’s Upgrade Might Change the Case for Investing in Hercules Capital (HTGC)

• Hercules Capital reported record third quarter 2025 financial results, with revenue of US$138.09 million and net income of US$119.69 million, and declared both a regular US$0.47 per share distribution and a US$0.07 special dividend, both paid in November 2025.
• In addition to these robust results, Hercules received an investment grade rating upgrade from Moody’s and achieved record new debt and equity commitments, highlighting strong business momentum and enhanced credit quality for the company.
• We’ll now examine how record-level loan originations in the latest quarter may reshape Hercules Capital’s investment narrative and outlook.

We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Hercules Capital Investment Narrative Recap

Being a Hercules Capital shareholder means believing in the company’s ability to sustain profitable growth by financing technology and life sciences firms while carefully managing credit risk in turbulent markets. The most important short-term catalyst remains robust new loan originations, seen in the latest record results, while persistent sector concentration risk is still a significant concern; the current earnings news does not fundamentally change either factor’s weighting in the near term. 

Among recent announcements, the special dividend of US$0.07 per share for Q3 2025 stands out, reflecting strong recent cash generation and ongoing confidence in coverage. This distribution, paid alongside the regular dividend, underscores Hercules Capital’s appeal for income-focused investors, especially relevant as growing commitments help cover these payouts and reinforce the lending platform’s reputation.

However, in contrast to strong growth headlines, investors should be aware that concentrated exposure to venture-backed technology and life science firms means that if industry cycles turn...

Read the full narrative on Hercules Capital (it's free!)

Hercules Capital's narrative projects $677.4 million in revenue and $455.0 million in earnings by 2028. This requires 10.4% yearly revenue growth and a $198.4 million increase in earnings from the current $256.6 million.

Uncover how Hercules Capital's forecasts yield a $21.22 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Six retail participants from the Simply Wall St Community estimate Hercules Capital’s fair value between US$16 and US$24.90, giving a broad range. These varied opinions sit against the backdrop of sector concentration risk potentially shaping future results, inviting you to review differing viewpoints.

Explore 6 other fair value estimates on Hercules Capital - why the stock might be worth as much as 40% more than the current price!

Build Your Own Hercules Capital Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Hercules Capital research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Hercules Capital research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hercules Capital's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com